{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T01:30:35Z","timestamp":1793323835245,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["from NIHR ARCs Dementia Capacity Building Post-Doctoral Training Scheme (DEM-COMM)"],"award-info":[{"award-number":["from NIHR ARCs Dementia Capacity Building Post-Doctoral Training Scheme (DEM-COMM)"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014013","name":"UK Research and Innovation","doi-asserted-by":"publisher","award":["MR\/W011581\/1"],"award-info":[{"award-number":["MR\/W011581\/1"]}],"id":[{"id":"10.13039\/100014013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cost Eff Resour Alloc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Alzheimer\u2019s disease is a progressive neurodegenerative disorders with profound impacts on cognitive function. There is a shortage of economic evidence relating to the impact that Alzheimer\u2019s disease has on healthcare costs and quality-adjusted life-years (QALYs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We estimated conventional multivariable models of the association between Alzheimer\u2019s disease and these core economic outcomes. However, these types of model may be confounded by omitted variables. We therefore also explored a causal approach using germline genetic variation as instrumental variables in a two-sample Mendelian randomization analysis including polygenic risk scores in a two-stage least squares model, inverse variance weighted models, and pleiotropy robust models. We studied outcomes in the UK Biobank cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Data from up to 310,838 individuals were analyzed.\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200955 cases of Alzheimer\u2019s disease were reported at or before recruitment into UK Biobank. A further\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009284 incident cases were identified over follow-up. Analysis of the prevalent cases suggested significant impacts on costs (\u00a31,140 in cases, 95% Confidence Interval (CI): \u00a3825 to \u00a31,456) and QALYs (-25%, 95% CI: -28% to -21%). Mendelian randomization estimates were imprecise for costs (\u00a33,082, 95% CI: -\u00a37,183 to \u00a313,348) and QALYs (-32%, 95% CI: -149% to 85%), likely due to the small proportion of variance (0.9%) explained in Alzheimer\u2019s disease status by the most predictive set of SNPs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Implications<\/jats:title>\n                    <jats:p>Conventional multivariable models suggested important impacts of Alzheimer\u2019s disease on inpatient hospital costs and QALYs, although this finding was based on very few cases. Mendelian randomization was very imprecise. Larger GWAS of clinical cases, improved understanding of the architecture of the disease, and the follow-up of cohorts until old age and death will help overcome these challenges.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12962-025-00684-y","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T01:57:35Z","timestamp":1765331855000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Associations of Alzheimer\u2019s disease with inpatient hospital costs and with quality-adjusted life years: evidence from conventional and Mendelian randomization analyses in the UK Biobank"],"prefix":"10.1186","volume":"24","author":[{"given":"Padraig","family":"Dixon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"issue":"10284","key":"684_CR1","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","volume":"397","author":"P Scheltens","year":"2021","unstructured":"Scheltens P, De Strooper B, Kivipelto M, Holstege H, Ch\u00e9telat G, Teunissen CE, et al. Alzheimer\u2019s disease. Lancet. 2021;397(10284):1577\u201390.","journal-title":"Lancet"},{"issue":"2","key":"684_CR2","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/S2468-2667(21)00249-8","volume":"7","author":"Estimation of the global prevalence of dementia","year":"2022","unstructured":"Estimation of the global prevalence of dementia. In 2019 and forecasted prevalence in 2050: an analysis for the global burden of disease study 2019. Lancet Public Health. 2022;7(2):e105\u201325.","journal-title":"Lancet Public Health"},{"key":"684_CR3","doi-asserted-by":"crossref","unstructured":"Nichols E, Szoeke CEI, Vollset SE, Abbasi N, Abd-Allah F, Abdela J, et al. Global,regional, and national burden of Alzheimer\u2019s disease and other dementias, 1990\u20132016:a systematic analysis for the global burden of disease study 2016. The Lancet Neurology.2019;18(1):88\u2013106.","DOI":"10.1016\/S1474-4422(18)30403-4"},{"key":"684_CR4","doi-asserted-by":"crossref","unstructured":"Soria Lopez JA, Gonz\u00e1lez HM, L\u00e9ger GC. Chapter 13 - Alzheimer\u2019s disease. In: Dekosky ST, Asthana S, editors. Handbook of Clinical Neurology. Elsevier; 2019;167:231\u201355.","DOI":"10.1016\/B978-0-12-804766-8.00013-3"},{"key":"684_CR5","doi-asserted-by":"crossref","unstructured":"Knapp M, Wong G. Economics and dementia: challenges and responses. Dementia. 2023:14713012231193141.","DOI":"10.1177\/14713012231193141"},{"issue":"1","key":"684_CR6","first-page":"e12360","volume":"8","author":"F Landeiro","year":"2022","unstructured":"Landeiro F, Morton J, Gustavsson A, Potashman M, Lecomte P, Belger M, et al. Health economic modeling for alzheimer\u2019s disease: expert perspectives. Alzheimer\u2019s Dementia: Translational Res Clin Interventions. 2022;8(1):e12360.","journal-title":"Alzheimer\u2019s Dementia: Translational Res Clin Interventions"},{"issue":"3","key":"684_CR7","doi-asserted-by":"publisher","first-page":"e1001779","DOI":"10.1371\/journal.pmed.1001779","volume":"12","author":"C Sudlow","year":"2015","unstructured":"Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015;12(3):e1001779.","journal-title":"PLoS Med"},{"key":"684_CR8","doi-asserted-by":"crossref","unstructured":"Dixon P, Davey Smith G, Hollingworth W. The association between adiposity and inpatient hospital costs in the UK Biobank cohort. Appl Health Econ Health Policy; 2018.","DOI":"10.1101\/399600"},{"key":"684_CR9","doi-asserted-by":"publisher","first-page":"102300","DOI":"10.1016\/j.jhealeco.2020.102300","volume":"70","author":"P Dixon","year":"2020","unstructured":"Dixon P, Hollingworth W, Harrison S, Davies NM, Davey Smith G. Mendelian randomization analysis of the causal effect of adiposity on hospital costs. J Health Econ. 2020;70:102300.","journal-title":"J Health Econ"},{"issue":"8","key":"684_CR10","doi-asserted-by":"publisher","first-page":"e1003725","DOI":"10.1371\/journal.pmed.1003725","volume":"18","author":"S Harrison","year":"2021","unstructured":"Harrison S, Dixon P, Jones HE, Davies AR, Howe LD, Davies NM. Long-term cost-effectiveness of interventions for obesity: A Mendelian randomisation study. PLoS Med. 2021;18(8):e1003725.","journal-title":"PLoS Med"},{"issue":"6","key":"684_CR11","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1177\/0272989X11401031","volume":"31","author":"PW Sullivan","year":"2011","unstructured":"Sullivan PW, Slejko JF, Sculpher MJ, Ghushchyan V. Catalogue of EQ-5D scores for the united Kingdom. Med Decis Mak. 2011;31(6):800\u20134.","journal-title":"Med Decis Mak"},{"issue":"7","key":"684_CR12","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/gepi.21998","volume":"40","author":"S Burgess","year":"2016","unstructured":"Burgess S, Davies NM, Thompson SG. Bias due to participant overlap in two-sample Mendelian randomization. Genet Epidemiol. 2016;40(7):597\u2013608.","journal-title":"Genet Epidemiol"},{"issue":"3","key":"684_CR13","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/s41588-019-0358-2","volume":"51","author":"BW Kunkle","year":"2019","unstructured":"Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Damotte V, Naj AC, et al. Genetic meta-analysis of diagnosed alzheimer\u2019s disease identifies new risk loci and implicates A\u03b2, tau, immunity and lipid processing. Nat Genet. 2019;51(3):414\u201330.","journal-title":"Nat Genet"},{"issue":"4","key":"684_CR14","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41588-022-01024-z","volume":"54","author":"C Bellenguez","year":"2022","unstructured":"Bellenguez C, K\u00fc\u00e7\u00fckali F, Jansen IE, Kleineidam L, Moreno-Grau S, Amin N, et al. New insights into the genetic etiology of alzheimer\u2019s disease and related dementias. Nat Genet. 2022;54(4):412\u201336.","journal-title":"Nat Genet"},{"key":"684_CR15","unstructured":"Mitchell R, Hemani G, Dudding T, Corbin L, Paternoster. L. UK Biobank genetic data: MRC-IEU quality control, version 2. 2019."},{"issue":"1","key":"684_CR16","first-page":"e12008","volume":"12","author":"AM Kulminski","year":"2020","unstructured":"Kulminski AM, Shu L, Loika Y, He L, Nazarian A, Arbeev K, et al. Genetic and regulatory architecture of alzheimer\u2019s disease in the APOE region. alzheimer\u2019s & dementia: diagnosis. Assess Disease Monit. 2020;12(1):e12008.","journal-title":"Assess Disease Monit"},{"issue":"9","key":"684_CR17","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41582-019-0228-7","volume":"15","author":"Y Yamazaki","year":"2019","unstructured":"Yamazaki Y, Zhao N, Caulfield TR, Liu C-C, Bu G. Apolipoprotein E and alzheimer disease: pathobiology and targeting strategies. Nat Reviews Neurol. 2019;15(9):501\u201318.","journal-title":"Nat Reviews Neurol"},{"key":"684_CR18","doi-asserted-by":"crossref","unstructured":"Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. The MR-Base platform supports systematic causal inference across the human phenome. Elife. 2018;7.","DOI":"10.7554\/eLife.34408"},{"issue":"1","key":"684_CR19","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s43586-021-00092-5","volume":"2","author":"E Sanderson","year":"2022","unstructured":"Sanderson E, Glymour MM, Holmes MV, Kang H, Morrison J, Munaf\u00f2 MR, et al. Mendelian randomization. Nat Reviews Methods Primers. 2022;2(1):6.","journal-title":"Nat Reviews Methods Primers"},{"issue":"9","key":"684_CR20","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41576-018-0020-3","volume":"19","author":"J-B Pingault","year":"2018","unstructured":"Pingault J-B, O\u2019Reilly PF, Schoeler T, Ploubidis GB, Rijsdijk F, Dudbridge F. Using genetic data to strengthen causal inference in observational research. Nat Rev Genet. 2018;19(9):566\u201380.","journal-title":"Nat Rev Genet"},{"issue":"1","key":"684_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ije\/dyg070","volume":"32","author":"G Davey Smith","year":"2003","unstructured":"Davey Smith G, Ebrahim S. Mendelian randomization\u2019: can genetic epidemiology contribute to Understanding environmental determinants of disease? Int J Epidemiol. 2003;32(1):1\u201322.","journal-title":"Int J Epidemiol"},{"issue":"R1","key":"684_CR22","doi-asserted-by":"publisher","first-page":"R89","DOI":"10.1093\/hmg\/ddu328","volume":"23","author":"G Davey Smith","year":"2014","unstructured":"Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Hum Mol Genet. 2014;23(R1):R89\u201398.","journal-title":"Hum Mol Genet"},{"key":"684_CR23","unstructured":"Kleiber C, Zeileis A, Zeileis MA. Package \u2018aer\u2019. R Package Version. 2020;12(4)."},{"issue":"500","key":"684_CR24","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1080\/01621459.2012.734171","volume":"107","author":"PS Clarke","year":"2012","unstructured":"Clarke PS, Windmeijer F. Instrumental variable estimators for binary outcomes. J Am Stat Assoc. 2012;107(500):1638\u201352.","journal-title":"J Am Stat Assoc"},{"key":"684_CR25","doi-asserted-by":"crossref","unstructured":"Burgess S, Small DS, Thompson SG. A review of instrumental variable estimators for Mendelian randomization. Stat Methods Med Res. 2015.","DOI":"10.1177\/0962280215597579"},{"key":"684_CR26","doi-asserted-by":"publisher","DOI":"10.1201\/b18084","volume-title":"Mendelian randomization: methods for using genetic variants in causal Estimation","author":"S Burgess","year":"2015","unstructured":"Burgess S, Thompson S. Mendelian randomization: methods for using genetic variants in causal Estimation. Boca Raton, Florida: CRC; 2015."},{"issue":"4","key":"684_CR27","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.3233\/JAD-131556","volume":"42","author":"L Colucci","year":"2014","unstructured":"Colucci L, Bosco M, Fasanaro AM, Gaeta GL, Ricci G, Amenta F. Alzheimer\u2019s disease costs: what we know and what we should take into account. J Alzheimers Dis. 2014;42(4):1311\u201324.","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"684_CR28","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3233\/JAD-190426","volume":"70","author":"YH El-Hayek","year":"2019","unstructured":"El-Hayek YH, Wiley RE, Khoury CP, Daya RP, Ballard C, Evans AR, et al. Tip of the iceberg: assessing the global socioeconomic costs of alzheimer\u2019s disease and related dementias and strategic implications for stakeholders. J Alzheimers Dis. 2019;70(2):323\u201341.","journal-title":"J Alzheimers Dis"},{"key":"684_CR29","unstructured":"Alzheimer\u2019s Association. 2023 Alzheimer\u2019s disease facts and figures. Chicago; 2023."},{"issue":"7","key":"684_CR30","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1111\/jgs.17345","volume":"69","author":"MP Aranda","year":"2021","unstructured":"Aranda MP, Kremer IN, Hinton L, Zissimopoulos J, Whitmer RA, Hummel CH, et al. Impact of dementia: health disparities, population trends, care interventions, and economic costs. J Am Geriatr Soc. 2021;69(7):1774\u201383.","journal-title":"J Am Geriatr Soc"},{"issue":"10","key":"684_CR31","doi-asserted-by":"publisher","first-page":"729","DOI":"10.7326\/M15-0381","volume":"163","author":"AS Kelley","year":"2015","unstructured":"Kelley AS, McGarry K, Gorges R, Skinner JS. The burden of health care costs for patients with dementia in the last 5 years of life. Ann Intern Med. 2015;163(10):729\u201336.","journal-title":"Ann Intern Med"},{"issue":"8","key":"684_CR32","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1177\/1471301219837776","volume":"19","author":"D Cantarero-Prieto","year":"2019","unstructured":"Cantarero-Prieto D, Leon PL, Blazquez-Fernandez C, Juan PS, Cobo CS. The economic cost of dementia: A systematic review. Dementia. 2019;19(8):2637\u201357.","journal-title":"Dementia"},{"issue":"1","key":"684_CR33","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/00005650-199901000-00005","volume":"37","author":"PJ Neumann","year":"1999","unstructured":"Neumann PJ, Kuntz KM, Leon J, Araki SS, Hermann RC, Hsu MA, Weinstein MC. Health utilities in alzheimer\u2019s disease: a cross-sectional study of patients and caregivers. Med Care. 1999;37(1):27\u201332.","journal-title":"Med Care"},{"key":"684_CR34","doi-asserted-by":"publisher","first-page":"101154","DOI":"10.1016\/j.ehb.2022.101154","volume":"46","author":"P Dixon","year":"2022","unstructured":"Dixon P, Harrison S, Hollingworth W, Davies NM, Davey Smith G. Estimating the causal effect of liability to disease on healthcare costs using Mendelian randomization. Econ Hum Biology. 2022;46:101154.","journal-title":"Econ Hum Biology"},{"issue":"5","key":"684_CR35","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1093\/ije\/dyaa114","volume":"49","author":"S Harrison","year":"2020","unstructured":"Harrison S, Davies AR, Dickson M, Tyrrell J, Green MJ, Katikireddi SV, et al. The causal effects of health conditions and risk factors on social and socioeconomic outcomes: Mendelian randomization in UK biobank. Int J Epidemiol. 2020;49(5):1661\u201381.","journal-title":"Int J Epidemiol"},{"issue":"7","key":"684_CR36","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/gps.5113","volume":"34","author":"R Wittenberg","year":"2019","unstructured":"Wittenberg R, Knapp M, Hu B, Comas-Herrera A, King D, Rehill A, et al. The costs of dementia in England. Int J Geriatr Psychiatry. 2019;34(7):1095\u2013103.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"1","key":"684_CR37","doi-asserted-by":"publisher","first-page":"100180","DOI":"10.1016\/j.ahr.2024.100180","volume":"4","author":"S Edwards","year":"2024","unstructured":"Edwards S, Trepel D, Ritchie C, Hahn-Pedersen JH, Robinson DE, Chan MS, et al. Real world outcomes, healthcare utilisation and costs of alzheimer\u2019s disease in England. Aging Health Res. 2024;4(1):100180.","journal-title":"Aging Health Res"},{"issue":"2","key":"684_CR38","doi-asserted-by":"publisher","first-page":"100234","DOI":"10.1016\/j.ahr.2025.100234","volume":"5","author":"S Edwards","year":"2025","unstructured":"Edwards S, Evans M, Ritchie C, Hahn-Pedersen JH, Chan MS, Bray BD, et al. The associations between multimorbidity, healthcare resource utilisation and costs in individuals with alzheimer\u2019s disease dementia. Aging Health Res. 2025;5(2):100234.","journal-title":"Aging Health Res"},{"issue":"1","key":"684_CR39","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s13195-020-00723-1","volume":"12","author":"F Landeiro","year":"2020","unstructured":"Landeiro F, Mughal S, Walsh K, Nye E, Morton J, Williams H, et al. Health-related quality of life in people with predementia alzheimer\u2019s disease, mild cognitive impairment or dementia measured with preference-based instruments: a systematic literature review. Alzheimers Res Ther. 2020;12(1):154.","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"684_CR40","doi-asserted-by":"publisher","first-page":"362","DOI":"10.14283\/jpad.2021.17","volume":"8","author":"MK Klie\u00df","year":"2021","unstructured":"Klie\u00df MK, Martins R, Connolly MP. Major cost drivers in assessing the economic burden of alzheimer\u2019s disease: A Structured, rapid review. J Prev Alzheimer\u2019s Disease. 2021;8(3):362\u201370.","journal-title":"J Prev Alzheimer\u2019s Disease"},{"issue":"5","key":"684_CR41","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.jval.2018.10.010","volume":"22","author":"P Dixon","year":"2019","unstructured":"Dixon P, Round J. Caring for carers: positive and normative challenges for future research on carer spillover effects in economic evaluation. Value Health: J Int Soc Pharmacoeconomics Outcomes Res. 2019;22(5):549\u201354.","journal-title":"Value Health: J Int Soc Pharmacoeconomics Outcomes Res"},{"key":"684_CR42","doi-asserted-by":"crossref","unstructured":"Al-Janabi H, Van Exel J, Brouwer W, Coast J. A framework for including family health spillovers in economic evaluation. Med Decis Mak. 2015.","DOI":"10.1177\/0272989X15605094"},{"issue":"1","key":"684_CR43","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12877-018-0751-1","volume":"18","author":"F Nickel","year":"2018","unstructured":"Nickel F, Barth J, Kolominsky-Rabas PL. Health economic evaluations of non-pharmacological interventions for persons with dementia and their informal caregivers: a systematic review. BMC Geriatr. 2018;18(1):69.","journal-title":"BMC Geriatr"},{"issue":"9","key":"684_CR44","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1017\/S1041610220004111","volume":"34","author":"F Pelone","year":"2022","unstructured":"Pelone F, Jacklin P, Francis JM, Purchase B. Health economic evaluations of interventions for supporting adult carers in the UK: a systematic review from the NICE guideline. Int Psychogeriatr. 2022;34(9):839\u201352.","journal-title":"Int Psychogeriatr"},{"issue":"4","key":"684_CR45","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s40273-019-00788-3","volume":"37","author":"P-J Lin","year":"2019","unstructured":"Lin P-J, D\u2019Cruz B, Leech AA, Neumann PJ, Sanon Aigbogun M, Oberdhan D, Lavelle TA. Family and caregiver spillover effects in Cost-Utility analyses of alzheimer\u2019s disease interventions. PharmacoEconomics. 2019;37(4):597\u2013608.","journal-title":"PharmacoEconomics"},{"issue":"10","key":"684_CR46","doi-asserted-by":"publisher","first-page":"e2131913","DOI":"10.1001\/jamanetworkopen.2021.31913","volume":"4","author":"P-J Lin","year":"2021","unstructured":"Lin P-J, Neumann PJ. Valuing alzheimer disease Therapies\u2014Considering costs and benefits beyond the patient. JAMA Netw Open. 2021;4(10):e2131913\u2013e.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"684_CR47","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12955-022-02036-3","volume":"20","author":"AD Keetharuth","year":"2022","unstructured":"Keetharuth AD, Hussain H, Rowen D, Wailoo A. Assessing the psychometric performance of EQ-5D-5L in dementia: a systematic review. Health Qual Life Outcomes. 2022;20(1):139.","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"684_CR48","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1038\/s41467-021-21073-y","volume":"12","author":"J Tyrrell","year":"2021","unstructured":"Tyrrell J, Zheng J, Beaumont R, Hinton K, Richardson TG, Wood AR, et al. Genetic predictors of participation in optional components of UK biobank. Nat Commun. 2021;12(1):886.","journal-title":"Nat Commun"},{"issue":"1","key":"684_CR49","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1093\/ije\/dyx206","volume":"47","author":"MR Munaf\u00f2","year":"2017","unstructured":"Munaf\u00f2 MR, Tilling K, Taylor AE, Evans DM, Davey Smith G. Collider scope: when selection bias can substantially influence observed associations. Int J Epidemiol. 2017;47(1):226\u201335.","journal-title":"Int J Epidemiol"},{"key":"684_CR50","doi-asserted-by":"crossref","unstructured":"Andrews SJ, Renton AE, Fulton-Howard B, Podlesny-Drabiniok A, Marcora E, Goate AM. The complex genetic architecture of Alzheimer\u2019s disease: novel insights and future directions. eBioMedicine. 2023;90.","DOI":"10.1016\/j.ebiom.2023.104511"},{"issue":"3","key":"684_CR51","doi-asserted-by":"publisher","first-page":"fcac125","DOI":"10.1093\/braincomms\/fcac125","volume":"4","author":"V Escott-Price","year":"2022","unstructured":"Escott-Price V, Hardy J. Genome-wide association studies for alzheimer\u2019s disease: bigger is not always better. Brain Commun. 2022;4(3):fcac125.","journal-title":"Brain Commun"}],"container-title":["Cost Effectiveness and Resource Allocation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-025-00684-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12962-025-00684-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-025-00684-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:13:29Z","timestamp":1781622809000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12962-025-00684-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["684"],"URL":"https:\/\/doi.org\/10.1186\/s12962-025-00684-y","relation":{},"ISSN":["1478-7547"],"issn-type":[{"value":"1478-7547","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,10]]},"assertion":[{"value":"21 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"UK Biobank cohort (research ethics approval reference 11\/NW\/0382.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7"}}